Energy use and related greenhouse gas emissions of ground water irrigated oil sunflower production

In this study, oil sunflower production irrigated by groundwater was analysed in regards to the energy efficiency and greenhouse gas (GHG) emission. This research was performed at 19 farms growing sunflower under the irrigation area of Konya-Başgötüren town groundwater irrigation cooperative for 2019 vegetation cycle. The farmers applying drip and sprinkler irrigation systems were 6 and 13, respectively and they applied different irrigation levels. In that regard, by grouping farmers in accordance of irrigation methods and irrigation water regimes, separate treatments were obtained. In the context of the research, inputs used, amount of inputs as well as yield were determined individually in the farmer basis. By using unit energy equivalent of inputs and GHG emission factors energy input and GHG emission were determined and were assessed by using the relevant indicators. In results, sunflower production with drip irrigation system was found more successful in regard to the energy productivity. None difference was found between both the irrigation systems in term of the environmental impact. Drip irrigation with 250-350 mm water application was found the most successful in respect to the yield, energy productivity and low GHG emission

Ege Üniversitesi Tıp Fakültesi Adli Tıp Anabilim Dalında raporları düzenlenen vertebra kırığı olgularının retrospektif olarak değerlendirilmesi: 2021-2022

Amaç: Maluliyet hesaplamaları Adli Tıp uygulamalarında önemli bir yer tutan ve maluliyet hesaplamasında kullanılan cetvellerindeki uygulama ve hesaplama farklarından doğan sorunlarla ilgili çalışmaların sıkça yapıldığı bir konudur. Yönetmeliklerin ekinde bulunan cetvellerin yaralanmanın değerlendirmesindeki bakış açılarının farklılığı, benzer arızalarda farklı sonuçlar ortaya çıkabilmesine, bazı olguların değerlendirmesinde yetersiz kaldığı durumlara neden olabilmektedir. Çalışmamızda çelişkili yorumlara neden olan ve ilgili yönetmeliklerdeki hesaplamalarda birden çok modeli bulunan ya da hiç karşılığı olmayabilen travmaya bağlı vertebra (omurga) kırığı olgularının değerlendirilmesi, maluliyet oranı değerlendirmesinde kullanılmakta olan yönetmelik maddelerinin tartışılması ve geliştirilmesi amaçlanmıştır. Gereç ve Yöntem: Çalışmamıza 01.05.2021-01.05.2022 tarihleri arasında vertebra kırığı nedeniyle maluliyet raporu düzenlenmiş 75 olgunun sosyodemografik verileri, olaya ilişkin bilgileri, yaralanan vertebra bölgesi ve kısmı, uygulanan tedavi, değerlendirmede kullanılan çeşitli yönetmeliklere göre maluliyet oranları kaydedilerek frekans ve anlamlılık analizleri yapılmıştır. Bulgular: Olguların %84’ünde konservatif tedavi uygulanmışken %16’sında cerrahi tedavi tercih edilmiştir. Olguların meslekte kazanma gücünde azalma oranı ortalama 9,2±15,1, yaralanma modeline göre engellilik oranı 11,4±6,7, eklem hareket açıklığı modeline göre ise 9,6±7,4 olarak bulunmuştur. Korpus (gövde) kırığı olanların çoğunluğunda yaralanma mekanizması araç içi trafik kazası olarak bulunmuştur (p=0,013). Yalnızca korpus kırığı olan olgularda yaralanma modeline göre hesaplanan engellilik oranı eklem hareket açıklığı modeline göre hesaplanan engellilik oranından yüksek bulunmuştur (p=0,021). Cerrahi tedavi seçilen olgularda meslekte kazanma gücünde azalma oranı ve her iki modele göre hesaplanan engellilik oranları konservatif tedavi seçilenlere göre yüksek bulunmuştur (sırasıyla p=0,001, p=0,022 ve p=0,001). Sonuç: Vertebra yaralanmalarına bağlı maluliyet hesaplamalarında kullanılan yönteme göre değişen oranlar, itirazlar nedeniyle genellikle kişiler hakkında birden çok rapor düzenlenmesine, dolayısıyla hukuki sürecin uzamasına ve mağduriyetin artmasına neden olmaktadır. Bu sebeple bu tür travmalarda haksız kazanç ya da kayıpların önlenmesi ve hukuki sürecin uzamaması için her üç yönetmelikte de değişiklikler yapılması ya da kapsamlı tek bir yönetmelik üzerinde çalışılması gerektiğini düşünmekteyiz

A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia

Objective: The aim of the present study was to evaluate the efficacy and safety of eltrombopag, an oral thrombopoietin receptor agonist, in patients with chronic immune thrombocytopenia (ITP). Materials and Methods: A total of 285 chronic ITP patients (187 women, 65.6%; 98 men, 34.4%) followed in 55 centers were enrolled in this retrospective cohort. Response to treatment was assessed according to platelet count (/mm3) and defined as complete (platelet count of >100,000/mm3), partial (30,000-100,000/mm3 or doubling of platelet count after treatment), or unresponsive (<30,000/mm3). Clinical findings, descriptive features, response to treatment, and side effects were recorded. Correlations between descriptive, clinical, and hematological parameters were analyzed. Results: The median age at diagnosis was 43.9±20.6 (range: 3-95) years and the duration of follow-up was 18.0±6.4 (range: 6-28.2) months. Overall response rate was 86.7% (n=247). Complete and partial responses were observed in 182 (63.8%) and 65 (22.8%) patients, respectively. Thirty-eight patients (13.4%) did not respond to eltrombopag treatment. For patients above 60 years old (n=68), overall response rate was 89.7% (n=61), and for those above 80 years old (n=12), overall response rate was 83% (n=10). Considering thrombocyte count before treatment, eltrombopag significantly increased platelet count at the 1st, 2nd, 3rd, 4th, and 8th weeks of treatment. As the time required for partial or complete response increased, response to treatment was significantly reduced. The time to reach the maximum platelet levels after treatment was quite variable (1-202 weeks). Notably, the higher the maximum platelet count after eltrombopag treatment, the more likely that side effects would occur. The most common side effects were headache (21.6%), weakness (13.7%), hepatotoxicity (11.8%), and thrombosis (5.9%). Conclusion: Results of the current study imply that eltrombopag is an effective therapeutic option even in elderly patients with chronic ITP. However, patients must be closely monitored for response and side effects during treatment. Since both response and side effects may be variable throughout the follow-up period, patients should be evaluated dynamically, especially in terms of thrombotic risk factors.PubMedWoSScopu

A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience

Objective: The aim of the present study was to evaluate the efficacy and safety of eltrombopag, an oral thrombopoietin receptor agonist, in patients with chronic immune thrombocytopenia (ITP)

A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience

Objective: The aim of the present study was to evaluate the efficacy and safety of eltrombopag, an oral thrombopoietin receptor agonist, in patients with chronic immune thrombocytopenia (ITP). Materials and Methods: A total of 285 chronic ITP patients (187 women, 65.6 \%; 98 men, 34.4\%) followed in 55 centers were enrolled in this retrospective cohort. Response to treatment was assessed according to platelet count (/mm(3)) and defined as complete (platelet count of >100,000/mm(3)), partial (30,000-100,000/mm(3) or doubling of platelet count after treatment), or unresponsive (<30,000/mm(3)). Clinical findings, descriptive features, response to treatment, and side effects were recorded. Correlations between descriptive, clinical, and hematological parameters were analyzed. Results: The median age at diagnosis was 43.9 +/- 20.6 (range: 3-95) years and the duration of follow-up was 18.0 +/- 6.4 (range: 6-28.2) months. Overall response rate was 86.7\% (n=247). Complete and partial responses were observed in 182 (63.8\%) and 65 (22.8\%) patients, respectively. Thirty-eight patients (13.4\%) did not respond to eltrombopag treatment. For patients above 60 years old (n=68), overall response rate was 89.7\% (n=61), and for those above 80 years old (n=12), overall response rate was 83\% (n=10). Considering thrombocyte count before treatment, eltrombopag significantly increased platelet count at the 1st, 2nd, 3rd, 4th, and 8th weeks of treatment. As the time required for partial or complete response increased, response to treatment was significantly reduced. The time to reach the maximum platelet levels after treatment was quite variable (1-202 weeks). Notably, the higher the maximum platelet count after eltrombopag treatment, the more likely that side effects would occur. The most common side effects were headache (21.6\%), weakness (13.7\%), hepatotoxicity (11.8\%), and thrombosis (5.9\%). Conclusion: Results of the current study imply that eltrombopag is an effective therapeutic option even in elderly patients with chronic ITP. However, patients must be closely monitored for response and side effects during treatment. Since both response and side effects may be variable throughout the follow-up period, patients should be evaluated dynamically, especially in terms of thrombotic risk factors